Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metaplasia Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
fosbretabulin, Saline
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced May 22, 2026, 1:43 AM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years to 110 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
118
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related, Maculopathy, Age-Related, Retinal Degeneration, Retinal Neovascularization, Gene Therapy, Therapy, Gene, Eye Diseases
Interventions
AAV2-sFLT01
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
15 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced May 22, 2026, 1:43 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Subconjunctival aflibercept, Placebo: Standard of care only
Drug · Other
Lead sponsor
Balamurali Ambati
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced May 22, 2026, 1:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
Intravitreal aflibercept injection 2.0mg
Drug
Lead sponsor
Gregg T. Kokame, MD
Other
Eligibility
25 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced May 22, 2026, 1:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 1:43 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
Interventions
CryoBalloon Focal Ablation System
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 1:43 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Ischemic Stroke, Neovascularization
Interventions
Tigertriever 13
Device
Lead sponsor
Rapid Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Thousand Oaks, California • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 1:43 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Dexlansoprazole, Dexlansoprazole Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Jacksonville, Florida • Chapel Hill, North Carolina • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced May 22, 2026, 1:43 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 1:43 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
episcleral brachytherapy
Radiation
Lead sponsor
Salutaris Medical Devices, Inc.
Industry
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
‘Aiea, Hawaii • Oak Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced May 22, 2026, 1:43 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Maculopathy, Age-Related, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2009 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions
tipifarnib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced May 22, 2026, 1:43 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Myelodysplastic Syndrome, Philadelphia Chromosome-negative CML, Myeloid Metaplasia, Myelofibrosis, Advanced Polycythemia, Non-Hodgkins Lymphoma
Interventions
TAK-901
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced May 22, 2026, 1:43 AM EDT